mesalazine
Salaza contains the active substance mesalazine, which is an anti-inflammatory medicine used to treat ulcerative colitis.
Salaza is indicated for the treatment of ulcerative proctitis, which is an inflammatory disease of the last part of the large intestine, i.e., the large intestine and rectum, for the purpose of:
Before starting treatment with Salaza, discuss it with your doctor or pharmacist.
During treatment with mesalazine, kidney stones may form. Symptoms may include pain in the sides of the abdomen and blood in the urine. It is recommended to drink sufficient fluids during treatment with mesalazine.
The doctor may monitor the patient's condition more frequently and order regular blood and urine tests.
Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have been reported with mesalazine treatment. If the patient experiences any symptoms of these severe skin reactions, they should stop using mesalazine and seek medical attention immediately (see section 4).
Mesalazine may cause reddish-brown discoloration of urine after contact with sodium hypochlorite bleach in toilet water. This is a chemical reaction between mesalazine and bleach and is harmless.
Tell your doctor or pharmacist about all medicines the patient is taking, has recently taken, or plans to take.
Before starting treatment with Salaza, tell your doctor if the patient is taking any of the following medicines (as the doctor may need to adjust the dose):
If the patient is pregnant, breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
Salaza can be used during pregnancy or breastfeeding only if the doctor recommends it.
This medicine does not affect the ability to drive or use machines.
This medicine should always be used as directed by the doctor. If in doubt, consult the doctor or pharmacist.
Method of administration:
This medicine can only be used rectally, i.e., it should be inserted into the rectum.
DO NOT take orally.
Before using the suppository, it is recommended to go to the toilet and empty the bowels.
It is recommended to insert the suppository while lying on the left side and remain in this position for about 1 hour.
The suppository should be inserted deeply into the rectum. The suppository should remain in the rectum for 1 to 3 hours to increase its effectiveness.
The doctor may adjust the dose depending on the patient's characteristics and the characteristics of the disease.
The recommended dose for adults is:
There is limited information on the use of Salaza in children under 18 years of age.
In case of overdose, consult a doctor, hospital, or emergency department for advice on the risk and further action. Take the packaging of the Salaza suppositories with you.
Do not take a double dose to make up for a missed dose.
It is important to use Salaza suppositories every day, even if the patient does not experience symptoms of ulcerative colitis. Continue treatment as directed by the doctor.
Do not stop treatment without consulting a doctor first.
If you have any further doubts about using this medicine, consult a doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
All medicines can cause allergic reactions, but severe allergic reactions are very rare. If the patient experiences any of the following symptoms after using this medicine, they should stop using the suppositories and seek medical attention immediately:
If the patient experiences fever, sore throat, or mouth sores, they should stop using the suppositories and seek medical attention immediately. These symptoms can very rarely be caused by a decrease in the number of white blood cells in the blood (a condition called agranulocytosis).
Severe side effects:
Stop using mesalazine and seek medical attention immediately if the patient experiences any of the following symptoms:
The following side effects have been reported in patients using mesalazine:
Rare side effects (may affect up to 1 in 1,000 people):
Very rare side effects (may affect up to 1 in 10,000 people):
Side effects with unknown frequency (frequency cannot be estimated from available data):
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medicine.
Do not store above 30°C.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton. The expiry date refers to the last day of the month.
Do not use this medicine if you notice signs of deterioration.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The suppositories are grayish-white to light purple-red, torpedo-shaped, in soft PVC/PE blister packs.
This medicine is available in packs of 12, 24, 30, or 100 suppositories.
Faes Farma, S.A.
Kalea Maximo Aguirre 14
48940 Leioa, Bizkaia
Spain
Faes Farma Portugal, S.A.
Rua Elias Garcia 28
2700-327 Amadora
Portugal
To obtain more detailed information, contact the local representative of the marketing authorization holder:
Recordati Polska sp. z o.o.
ul. Królewska 16
00-103 Warsaw
tel: +48 22 206 84 50
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.